Castor oil is one of the oldest drugs. When given orally, it has a laxative effect and induces labor in pregnant females. The effects of castor oil are mediated by ricinoleic acid, a hydroxylated fatty acid released from castor oil by intestinal lipases. Despite the wide-spread use of castor oil in conventional and folk medicine, the molecular mechanism by which ricinoleic acid acts remains unknown. Here we show that the EP 3 prostanoid receptor is specifically activated by ricinoleic acid and that it mediates the pharmacological effects of castor oil. In mice lacking EP 3 receptors, the laxative effect and the uterus contraction induced via ricinoleic acid are absent. Although a conditional deletion of the EP 3 receptor gene in intestinal epithelial cells did not affect castor oil-induced diarrhea, mice lacking EP 3 receptors only in smooth-muscle cells were unresponsive to this drug. Thus, the castor oil metabolite ricinoleic acid activates intestinal and uterine smooth-muscle cells via EP 3 prostanoid receptors. These findings identify the cellular and molecular mechanism underlying the pharmacological effects of castor oil and indicate a role of the EP 3 receptor as a target to induce laxative effects.
C
astor oil, also known as Oleum Palmae Christi, is obtained from the seeds of Ricinus communis and has been used therapeutically for centuries (1, 2), being first described in the Ebers papyrus of ancient Egypt more than 3,500 y ago (3) . Castor oil is a triglyceride characterized by a high content of the hydroxylated unsaturated fatty acid ricinoleic acid [(9Z,12R)-12-hydroxyoctadec-9-enoic acid] (4). After oral ingestion of castor oil, ricinoleic acid is released by lipases in the intestinal lumen, and considerable amounts of ricinoleic acid are absorbed in the intestine (5, 6) . The released ricinoleic acid induces a strong laxative effect (5, 7) . There is also a well-documented labor-inducing effect of castor oil in pregnant females at term; however, use of this drug for labor induction is not recommended because of unwanted effects, such as nausea (8) .
The mechanisms underlying the pharmacological effects of ricinoleic acid remain elusive. Castor oil is regarded as a stimulant and irritant laxative without known mechanism of action (9) . Several studies have shown that relatively high concentrations of ricinoleic acid can cause ultrastructural alterations in the villous tips of the intestinal mucosa (10, 11) . Given the high concentrations of ricinoleic acid used in these experiments, it is, however, not clear whether these unspecific morphological effects are relevant for the laxative effect of castor oil. In part, conflicting data have been published with regard to the ability of ricinoleic acid to induce procontractile effects on intestinal smooth muscle and to alter intestinal ion transport and water flux. Although some groups observed an inhibition of water and electrolyte absorption (12) (13) (14) , others found an activation of ion secretory processes by ricinoleid acid (15) . In addition to effects of ricinoleic acid on intestinal ion transport and water flux, evidence has been provided that ricinoleic acid can directly affect intestinal motility (16) (17) (18) (19) . Whether these effects are mediated by the enteric nervous system or are direct effects on intestinal smooth muscle remained unclear.
The present study was undertaken to elucidate the molecular mechanism underlying the biological effect of castor oil-derived ricinoleic acid. Based on cellular signaling studies and an siRNA screening approach, we identified prostaglandin E 2 receptors as targets of ricinoleic acid and show that the EP 3 receptor mediates the effects of castor oil on the motility of the uterus and the intestine.
Results
In a screen for potential receptor-mediated effects using a library of biologically active lipids, we observed a Ca 2+ transient after exposure of various cell types to ricinoleic acid. The response was strongest in the human megakaryocyte leukemia cell line MEG-01 (Fig. 1A) . This effect was dose-dependent with an EC 50 of 5 μM (Fig. 1B) and could be blocked by pretreatment of cells with pertussis toxin (Fig. 1A) . The biologically inactive trans isomer of ricinoleic acid, ricinelaidic acid [(9E,12R)-12-hydroxyoctadec-9-enoic acid], as well as the nonhydroxylated homolog, oleic acid [(9Z)-octadec-9-enoic acid], were without effect (Fig.  1B) . These data suggest that ricinoleic acid can specifically activate a G protein-coupled receptor (GPCR). To identify a putative GPCR activated by ricinoleic acid, we screened a small interfering RNA (siRNA) library targeting all known and predicted nonolfactory human GPCRs for its ability to interfere with activation of MEG-01 cells by ricinoleic acid. Fig. 1C shows that siRNA pools directed against mRNAs encoding EP 3 and EP 4 (20) (21) (22) strongly reduced ricinoleic acid effects in MEG-01 cells. We verified that EP 3 and EP 4 receptors are expressed in MEG-01 cells and that prostaglandin E 2 (PGE 2 ) has effects comparable to ricinoleic acid in these cells (Fig. S1 ). Consistent with a role of EP 3 and EP 4 receptors in mediating cellular effects of ricinoleic acid, the selective antagonists of EP 3 and EP 4 receptors, L-798,106 and L-161,982, respectively, at maximally active concentrations inhibited ricinoleic acid-and PGE 2 -induced calcium mobilization in MEG-01 cells (Fig. 1D) . EP 3 /EP 4 -mediated effects of ricinoleic acid were not because of formation of PGE 2 in response to ricinoleic acid ( Fig. S2 A and B) . Consistent with this finding, ricinoleic acid effects were not affected by inhibition of cyclooxygenase (COX)-1 and COX-2 (Fig. S2C) .
To further characterize the effects of ricinoleic acid on prostanoid receptors, we heterologously expressed prostanoid receptors together with the promiscuous G protein α-subunit Gα 15 (23) in CHO cells expressing a bioluminescent Ca 2+ -sensor (24) . Among the four human PGE 2 receptors (EP 1 -EP 4 ), only EP 3 and EP 4 responded to ricinoleic acid (Fig. 1E) . PGE 2 activated all four receptors, indicating that EP 1 and EP 2 were functionally expressed (Fig. 1E) . The biologically inactive ricinoleic acid isomer ricinelaidic acid was inactive (Fig. S3A) . Whereas ricinoleic acid was about one order-of-magnitude less potent than PGE 2 , the efficacy of ricinoleic acid to activate EP 3 and EP 4 receptors was comparable with that of PGE 2 (Fig. 1E) . Ricinoleic acid also activated murine EP 3 and EP 4 receptors (Fig. S3B) . None of the other prostanoid receptors, including IP, DP 1 , DP 2 , FP, and TP were activated by ricinoleic acid (Fig. 1F) . In contrast to oleic acid, ricinoleic acid was able to displace 3 H-PGE 2 from EP 3 receptors expressed in CHO cells with an IC 50 of 500 nM, but ricinelaidic acid hardly competed with PGE 2 for binding (Fig. 1G) . Taken together, these data show that ricinoleic acid is a selective agonist of EP 3 and EP 4 receptors.
We then analyzed mice lacking EP 3 or EP 4 receptors (25-27) to test whether these receptors play a role in ricinoleic acid-induced pharmacological effects in vivo. Mice lacking either EP 3 (Ptger3 ) showed normal intestinal transit time ( Fig. 2A) . When given castor oil, wild-type mice responded with a strong diarrhea, starting about 30 min after application. The laxative effect lasted for about 2 h. Interestingly, EP 3 receptor-deficient mice were completely unresponsive, whereas mice lacking EP 4 receptors responded like wild-type mice (Fig. 2B) . Similarly, ricinoleic acid given orally also induced a strong laxative effect, which was abrogated in mice lacking the EP 3 receptor (Fig. 2C ). Mice lacking EP 3 receptors were, however, indistinguishable from wild-type mice with regard to the effect of other laxatives, such as 5-hydroxytryptophan or polyethylene glycol (PEG3000) (Fig. 2D ). Because ricinoleic acid has been reported to induce formation of PGE 2 in the mammalian intestine (28), we tested the effect of COX inhibition on ricinoleic acid-induced diarrhea. Mice treated with COX-1 and COX-2 inhibitors responded normally to castor oil (Fig. 2E) . Thus, ricinoleic acid-induced laxative effects are not a result of formation of prostanoids but are the result of a direct activation of EP 3 receptors by ricinoleic acid.
To further analyze the role of EP 3 receptors in the pharmacological effects of castor oil, we performed in vitro experiments on isolated small intestine. In flux measurements on intestinal mucosa using the Ussing chamber, we did not observe any effect of ricinoleic acid, but carbachol induced a strong secretory effect ( Fig. 3 A and B) . However, myographic analysis of ileal segments of the small intestine from wild-type mice showed an increase in contractile activity in response to ricinoleic acid ( Fig. 3 C and I) , an effect insensitive to inhibition of COX-1 and COX-2 ( Fig. S4 ) and also seen in segments from EP 4 −/− mice ( Fig. 3 G and I) . In contrast to wild-type and EP 4 -deficient ileal segments, the small intestine of EP 3 −/− mice did not respond to ricinoleic acid ( Fig. 3  E and I ) but showed a similar response as intestine from wildtype and EP 4 −/− mice to the muscarinic receptor agonist carbachol (Fig. 3 D, F, H, and I) .
Expression of EP 3 receptors has been reported in the intestine as well as in the uterus, the major sites of ricinoleic acid effects (29) . In the mammalian intestine, EP 3 receptors have been shown to be expressed in epithelial cells, enteric ganglia cells, immune cells, as well as in longitudinal but not circular smoothmuscle layers (22, (29) (30) (31) . Using EP 3 receptor-deficient mice that express β-galactosidase instead of EP 3 (25), we could verify expression of EP 3 in some epithelial cells, as well as in the longitudinal smooth-muscle layer of the intestine (Fig. S5) . To test which cell type in the intestine mediates EP 3 receptor-dependent laxative effects of ricinoleic acid, we mated mice carrying a conditional allele of the EP 3 receptor (Ptger3 flox ) (27) with mice expressing the recombinase Cre, either under the control of the villin promoter (32) (villin-Cre) or the smooth-muscle myosin heavy-chain promoter (SMMHC-CreER T2 ) (33) to specifically induce EP 3 receptor-deficiency in epithelial cells or in smoothmuscle cells, respectively. The response to castor oil given orally was indistinguishable between wild-type, SMMHC-CreER ] i in CHO-K1 cells expressing no receptor (ø) or DP 1 , DP 2 , FP, EP 3 , EP 4 , IP, or TP together with a promiscuous G protein α-subunit. (G) Effect of PGE 2 , ricinoleic acid, ricinelaidic acid, and oleic acid at the indicated concentrations on binding of 3 H-PGE 2 to CHO cells expressing the human EP 3 receptor. Shown are mean values ± SEM, n ≥ 3. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; n.s., not significant compared with RA or PGE 2 alone (D) or compared with nontransfected cells (ø; F). (Fig. 4A) . In contrast, mice in whom EP 3 deficiency was induced specifically in smooth-muscle cells (SMMHC-CreER T2 ;EP 3 flox/flox ) were completely unresponsive (Fig. 4A) . The laxative effects of other stimuli, like 5-hydroxytryptophan and PEG3000, were not affected by smooth muscle-specific EP 3 deficiency, indicating that these animals were responsive to diarrhea-inducing agents ( Fig. 4B and Fig. S6 ). In addition, we verified absence of EP 3 encoding mRNA in the intestinal smooth-muscle layer of smooth muscle-specific EP 3 knockout (Fig. S7A) , and we found no difference in basal intestinal function of smooth muscle-specific EP 3 receptor-deficient mice compared with wild-type animals (Fig. S7B) . As expected from the in vivo experiments, intestinal segments from smooth muscle-specific EP 3 receptor-deficient mice were not contracted by ricinoleic acid but still responded to carbachol (Fig. 4 C-F) . Thus, EP 3 receptors on intestinal smooth-muscle cells mediate the laxative effects of ricinoleic acid released from castor oil.
Given the labor-inducing effects of castor oil and the expression of EP 3 in the myometrium (7, 8, 34, 35) (Fig. S5C) , we measured the effect of ricinoleic acid on contractility in nonpregnant and pregnant uteri. Whereas nonpregnant and pregnant wild-type uteri showed a strong increase in magnitude and frequency of contractions when exposed to ricinoleic acid (Fig. 5 A, E, F, J, and K), uteri from EP 3 receptor-deficient mice did not respond at all (Fig. 5 C, E , H, J, and K). Both wild-type and EP 3 -deficient uteri from nonpregnant and pregnant mice contracted when exposed to carbachol (Fig. 5 B, D , E, G, I, J, and K).
Discussion
Castor oil, a natural triglyceride containing mainly ricinoleic acid, has a long history as a remedy because of its various biological effects, including an increase in propulsive intestinal motility. Based on the observation that ricinoleic acid, which is released from castor oil by intestinal lipases, induces calcium transients in various cells, and by using a siRNA screen against all nonolfactory GPCRs, we found that ricinoleic acid is a selective agonist of EP 3 and EP 4 receptors. Using mice with constitutive and conditional EP 3 or EP 4 receptor deficiency, we show that the pharmacological effects of castor oil are mediated by activation of EP 3 receptors on smooth-muscle cells. This discovery provides the long-sought mechanism of action of one of the oldest drugs, which is still used in conventional, alternative, and folk medicine. The unexpected, highly specific mechanism of action may promote a reevaluation of the medical use of castor oil and suggests novel approaches to increase intestinal motility.
Consistent with a specific mechanism, the pharmacological activity of ricinoleic acid shows a strong dependency on the structure of the drug as the trans isomer ricinelaidic acid, as well as the nonhydroxylated fatty acid oleic acid are without effect (7). This structure-activity relationship can also be found with regard to the ability of ricinoleic acid and related fatty acids to activate the EP 3 and EP 4 receptor. Although both PGE 2 and ricinoleic acid are unsaturated and hydroxylated fatty acids, the ability of ricinoleic acid to act as an EP 3 /EP 4 receptor agonist was not foreseeable with the currently available tools. Given the high specificity of ricinoleic acid for EP 3 and EP 4 receptors, it may be of interest to further explore the potential of hydroxylated fatty acids to specifically activate prostanoid receptors. PGE 2 and EP receptors have been implicated in the regulation of intestinal and uterine functions (30, 34) . Both, pharmacological and molecular biology studies showed the presence of EP 3 receptors in the pregnant uterus, and activation of EP 3 receptors has been demonstrated to evoke contraction of uterine smooth muscle (35, 36) . In fact, the PGE 1 and PGE 2 analogs misoprostol and sulprostone can be used to induce labor (37) . In the small intestine, EP 3 receptors are expressed in smoothmuscle cells, neurons, as well as in some epithelial cells. Although the procontractile effect of PGE 2 on isolated intestinal smooth muscle involves EP 1 , EP 3 , and FP receptors (38) , it has been unclear which receptor is responsible for the increase in peristalsis induced by PGE 2 (39) . Based on in vitro studies using to the pharmacological effects of castor oil-derived ricinoleic acid. In animals with blocked COX-1 and COX-2 activity, castor oil-and ricinoleic acid-induced effects were not affected. Thus, PGE 2 , which may be formed in response to ricinoleic acid, is not sufficient to mediate the effects, and ricinoleic acid acting on EP 3 receptors is responsible for castor oil-induced laxative and laborinducing effects. The clinical use of castor oil as a laxative has been decreasing in conventional medicine, but castor oil is still used widely in alternative and folk medicine. Lack of knowledge regarding the mechanism of action of castor oil may have contributed to the reduced use of castor oil in academic medicine. Despite older reports that castor oil, when given in adequate doses, is a welltolerated and safe laxative (40) , more recently the general view has emphasized the unwanted effects of castor oil, such as unpleasant taste, cramps, and danger of fluid and electrolyte losses because of stimulation of water and electrolyte secretion (9) . Regarding the basic mechanism of the laxative effect, we found no evidence for an effect of ricinoleic acid on electrolyte and water fluxes in the mucosa of the ileum and the colon. Instead, castor oil and ricinoleic acid induce contraction of intestinal smooth muscle, an effect that is consistent with the expression of the EP 3 receptor in the longitudinal smooth-muscle layer of the intestinum. These data provide a mechanism underlying the laxative effects of castor oil, and they suggest that an orally available specific EP 3 receptor agonist with high first-pass effect may be a relatively safe laxative that produces an efficient properistaltic effect without causing additional water and electrolyte losses because of prosecretory effects.
The fact that ricinoleic acid also acts on EP 4 receptors raises the question whether some of the castor oil effects are also mediated by this prostanoid receptor subtype. In mice lacking EP 4 receptors, castor oil-induced laxation was not affected, strongly indicating that this effect indeed requires EP 3 but not EP 4 receptors. Given the expression of EP 4 receptor in some epithelial cells of the intestine, as well as in immune cells (31, 41) , it may be interesting to test the effect of castor oil on regenerative and inflammatory processes involving the intestinal epithelium (42, 43) .
Here we report on the mechanism by which castor oil exerts its effects on gut and uterus motility. We show that the active component of castor oil, ricinoleic acid, is a selective agonist of EP 3 and EP 4 receptors, and that the pharmacological effects of castor oil are mediated by activation of EP 3 receptors on smooth-muscle cells. This remarkable specificity of the mechanism of action of castor oil is rather unexpected because castor oil has been regarded as an agent that exerts its effects through unspecific mechanisms. In addition, our data indicate that EP 3 receptors are potential targets for drugs to induce laxation.
Methods
Reagents. Ricinoleic acid, ricinelaidic acid, oleic acid, carbachol, 5-hydroxytryptophan, PEG3000, and pertussis toxin were from Sigma-Aldrich. PGE 2 (24) were seeded in 96-well plates and transfected with indicated cDNAs or control DNA (50 ng/well) using FuGENE6 reagent (Roche Diagnostics), as previously described (44) . Two days after transfection, cells were loaded with 5 μM coelenterazine h (Invitrogen) in calcium-free HBSS containing 10 mM Hepes, pH 7.4, for 3.5 h at 37°C. Forty-five minutes before experiments, the buffer was replaced with HBSS containing 1.8 mM CaCl 2 . Measurements were performed by using a luminometer plate reader (Luminoskan Ascent; Thermo Electron). The area under each calcium transient (measured for 1 min) has been calculated using Ascent software (Thermo Electron) and expressed as AUC.
siRNA Screening. Four separate siRNAs of a siRNA library directed against 514 genes including 407 nonolfactory human GPCRs and 86 olfactory human GPCRs (Qiagen) targeting the same mRNA were pooled. MEG-01 cells were reverse-transfected with siRNA pools at a final concentration of 5 nM for each siRNA. Seventy-two hours later, cells were loaded with Fura-2/AM and ricinoleic acid-induced calcium transients were recorded and analyzed as described above. Ratios of AUC of ricinoleic acid induced calcium transients in cells transfected with siRNA pools targeting a particular GPCR and AUC of effects in cells transfected with scrambled siRNA were determined.
RT-PCR. RNA was isolated from MEG-01 cells with the RNeasy Mini Kit (Qiagen). For reverse-transcription reaction, 1 μg total RNA was reversetranscribed. cDNA synthesis was monitored by PCR of a 401-bp fragment of glyceraldehyde-3-phosphate dehydrogenase.
Genetic Mouse Models. EP 3 -and EP 4 -deficient mice have been described previously (25, 26) were performed at least 7 d after the last injections. All animal experiments were approved by the Regierungspräsidia Karlsruhe and Darmstadt.
Determination of Laxative Effects. To measure the laxative effects of different substances, mice were starved 16 h before the experiments. On the day of the experiment, mice were treated with the indicated substances, and the bottom of the cages was covered with white tissue paper. The weight of shapeless and watery stools was determined hourly.
Determination of Intestinal Transit Time. Total intestinal transit time was measured as described previously (46) . Briefly, mice were given carmine red solution orally (150 μL tap water containing 3 mg carmine red). Mice were returned to individual cages covered with white paper. The time taken until the excretion of red feces was measured.
Myography. See SI Methods.
Ussing Chamber Experiments. See SI Methods.
Radioligand Binding Assay. See SI Methods.
Statistics. Unless indicated, data are expressed as means ± SEM. Statistical analyses of differences between two groups were performed by nonparametric, unpaired, two-tailed Mann-Whitney test. A P value less than 0.05 was considered significant.
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